MRS 2500 tetraammonium saltCat. No. 2159 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (1R*,2S*)-4-[2-Iodo-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester tetraammonium salt |
Biological Activity
Highly potent and selective antagonist of the platelet P2Y1 receptor (Ki = 0.78 nM). Inhibits ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Inhibits the upregulation of NTPDase1 by ATPγS. Prevents thrombus formation in vivo.Licensing Information
Sold under license from the NIH, US Patent 10/169975Certificate of Analysis / Safety Data Sheet
References
Kim et al (2003) 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J.Med.Chem 46 4974. PMID: 14584948.
Cattaneo et al (2004) Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor. Biochem.Pharmacol. 68 1995. PMID: 15476670.
Hechler et al (2006) MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3', 5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J.Pharmacol.Exp.Ther. 316 556. PMID: 16236815.
Lu et al (2007) Stimulation of the P2Y1 receptor up-regulates nucleoside-triphosphate diphosphohydrolase-1 in human retinal pigment epithelial cells. J.Pharmacol.Exp.Ther. 323 157. PMID: 17626796.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: MRS 2500 tetraammonium salt, supplier, potent, selective, P2Y1, antagonists, Receptors, Purinergic, purinoceptors, MRS2500, prevents, thrombus, formation
Quick Order
Find multiple products by catalog number
New Products in this Area
GPR35 agonist; more potent than zaprinast (Cat. No. 0947)
H2L 5765834LPA1,3,5 antagonist
CYM 50308Potent and selective S1P4 agonist
H2L5186303Potent and selective LPA2 receptor antagonist
MEDICA 16FFA1 (GPR40) agonist. Also inhibits ATP citrate lyase
BX 471Potent, selective CCR1 antagonist
PF 04418948Potent and selective EP2 receptor antagonist
LatanoprostFP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors
GRI 977143Selective LPA2 receptor non-lipid agonist
CYM 50260Potent and selective S1P4 agonist
G-36Selective GPR30 antagonist
Strontium chlorideCalcium sensing receptor (CaSR) agonist
CS 2100Selective S1P1 agonist
SMANT hydrochlorideInhibits Smoothened (Smo) accumulation
TUG 891Potent and selective GPR120 agonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.






